MBX Biosciences, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -35.41% | -17.89% | -40.45% | -45.88% | -63.18% |
| Total Depreciation and Amortization | 22.10% | 59.34% | 83.61% | 52.42% | 93.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 552.46% | 428.82% | 108.29% | 10.38% | -21.47% |
| Change in Net Operating Assets | 90.99% | -115.10% | -65.74% | -126.18% | 163.64% |
| Cash from Operations | -16.74% | -16.25% | -46.21% | -56.03% | -65.25% |
| Capital Expenditure | -185.55% | -270.21% | -120.71% | -46.71% | -10.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.15% | -5.53% | 48.80% | 83.65% | -251.95% |
| Cash from Investing | -30.15% | -6.50% | 47.88% | 82.75% | -247.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.66% | 59.17% | 8.81% | 8.49% | 63,913.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -7.31% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 49.45% | 73.49% | 82.24% | 85.53% | -36.65% |
| Cash from Financing | 17.30% | 18.42% | -19.01% | -19.31% | 254.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -46.67% | 380.99% | 37.76% | 44.97% | 271.16% |